

NEW CLINICAL TRIAL OPEN FOR INCLUSION

PROTOCOL TITLE

A phase 3, randomized, double-blind, placebo-controlled study of mevrometostat (PF-06821497) with enzalutamide in metastatic castration-sensitive prostate cancer (MEVPRO-3)

ALIAS

MEVPRO-3

CTO NUMBER

CTO25011PFI


SPONSOR

Pfizer

KEY INCLUSION AND EXCLUSION CRITERIA

- mCSPC documented by bone scan (bone disease) or metastatic lesions on CT/MRI (soft tissue).
- No prior EZH2i.
- No prior systemic therapies for mCSPC.
- ARPI therapy is not allowed in any prior setting for prostate cancer
- Prior treatment allowed with up to 3 months of ADT and 1 course of palliative surgery or radiation to treat symptoms of metastatic disease.

DESIGN



Opmerking: in principe geen inclusie “de novo, low volume” patiënten gezien geen mogelijkheid tot radiotherapie op de prostaat (zie exclusie criteria).

PRINCIPAL INVESTIGATOR

Naam Simon Van Wambeke
Simon.vanwambeke@zas.be

STUDY COORDINATOR(S)

An Van Extergem
An.vanextergem@zas.be

Abdelbari Baitar
Abdelbari.baitar@zas.be